

Obesity in SMS: Causes and Strategies for Treatment

Stephanie Sisley, MD

Baylor
College of
Medicine



Baylor
College of
Medicine



**Texas Children's
Hospital®**



Disclosures

This presentation discusses the use of off-label medications

I have done speaking and consulting work for Rhythm Pharmaceuticals

Baylor
College of
Medicine

Overview

- What we know
- Where we are
- Where we might be going



**Texas Children's
Hospital**[®]






What We Know



The Definition of Obesity



Adult Definition =
BMI \geq 30

Pediatrics Definition =
BMI \geq 95%ile


Why Do We Care?




The Common Belief for Obesity Causes





Texas Children's
Hospital®



A Simplified View of Obesity Causes





SMS, *RAI1*, and Obesity



Hippocampus -
Memory




Influences on Satiety Hormones




Decreased production of *bdnf* leads to decreased *pomc*



Epigenetics Contributes to Obesity





Processed Foods and Weight Gain












Variable Response to Diet



Variable Response to Exercise




Exercise Effects in Children



Altered Physiology and Obesity

- Disease Processes: Cushing's, Hypothyroidism, Puberty
- Environmental causes
- Iatrogenic: Insulin, steroids, anticonvulsants, antipsychotics



Relationship Between Medications and Weight in SMS

↑ Maladaptive food behaviors in

- Individuals with overweight/obesity
- Individuals on anti-anxiety/depressant medications



Resource for Medications

<https://www.obesityaction.org/resources/prescription-medications-weight-gain/>





Texas Children's
Hospital®






Drug Class /Type (and Potential Related Weight Gain)	Common Name	Proprietary or Brand Name	Alternative Drugs (Weight neutral or may promote weight-loss)
Diabetes Therapies (may cause up to 8 kg weight gain in an intensive 3-month treatment course)			
Insulin	insulin lispro insulin aspart insulin glulisine	Humalog® Novolog® Apidra®	metformin (Glucophage®, Glucophage® XR, Fortamet®, Glumetza®, Riomet®, generics)
Thiazolidinediones (TZDs)	pioglitazone	Actos®	Linagliptin (Tradjenta®) saxagliptin (Onglyza®) sitagliptin (Januvia®) exenatide(Byetta®) Liraglutide (Victoza®) acarbose (Prandase®, Precose®) miglitol (Glyset®)
Sulfonylureas (SUs) <i>usually ≤5 kg gain during 3-12 months of treatment</i>	glipizide glyburide glimepiride chlorpropamide tolbutamide	Glucotrol® Glucotrol® XL Diabeta® Micronase® Glynase® Amaryl® Diabinese® generics	<i>These combination products tend to have fewer side-effects and less weight gain:</i> metformin/pioglitazone (Actoplus Met®) glipizide/metformin (Metaglip®) glyburide/metformin (Glucovance®) glimepiride



Circadian Rhythm Disruption and Weight




The Body Fights Back



Adaptation to Weight Loss



Other Influences





Where We Are



When to Use Pharmacotherapy

	Adult	Pediatric
No comorbidity	BMI \geq 30	BMI \geq 120% of 95 th %ile or BMI \geq 35
With comorbidity	BMI \geq 27	BMI \geq 95 th %ile or BMI \geq 30




- Failure of lifestyle therapies
- Long term use if \geq 5% BMI reduction after 12 weeks

Effects of Pharmacotherapy




Texas Children's
Hospital®




Metabolic Surgery

Roux-en Y
(RYGB or
“Gastric bypass”)



Vertical Sleeve
Gastrectomy (VSG or
“sleeve”)



Effect of Metabolic Surgery


Diet and exercise

Drug therapy


Bariatric surgery



Texas Children's
Hospital®



Variable Response in Bariatric Surgery



Baylor
College of
Medicine

Want to Off-Road?



Texas Children's
Hospital®






Thinking Outside the Box...

- Diabetes medications with weight reducing effects: SGLT2, exenatide, tirzepatide
- Pediatrics: topiramate, naltrexone, bupropion
- Stimulants
- **There are no approved drugs in pediatrics under age 12 for weight management**

Methylphenidate Weight Outcomes



Texas Children's
Hospital®






Comparison of Stimulants on Weight in Adolescents






Flexible
LDX 30->70
Mean ~50

MPH 18->72
Mean ~45



Forced
LDX 30->70

MPH 18->72




LDX=lisdexamfetamine

MPH=osmotic-release methylphenidate

Combination Therapy

●	Liraglutide	1, 6, 7
■	Lorcaserin	1, 2, 3, 4, 6
■	Nal-Bup	1, 4, 5, 6, 8, 9
▲	Phen-Top*	5, 10*




↓
Appetite suppression
↓ caloric intake
↓ food reward

* from mice studies


1	parietal cortex	6	insula
2	visual cortex	7	putamen
3	amygdala	8	anterior cingulate
4	hippocampus	9	frontal gyrus
5	hypothalamus	10	nucleus accumbens

Orlistat




↓ lipid absorption

Liraglutide




Slows gastric emptying
↓ gastric motility & HCl secretion





↑ insulin secretion

Combination Therapy – Topiramate+Phentermine



Combination Therapy- Oxytocin+Naltrexone



Baylor
College of
Medicine

Where We Might Be Going



Texas Children's
Hospital®

In the pipeline

- Tesomet: tesofensine+metoprolol for hypothalamic obesity and PWS (Phase 2b, 2023)
- Semaglutide: once weekly GLP-1R agonist
 - Diabetes: PIONEER TEENS NCT04596631
 - Obesity: NCT04102189
- Oxytocin: NCT04551482, NCT02849743 (Hypothalamic Obesity)




Texas Children's
Hospital®



Examining All Causes of Obesity



Texas Children's
Hospital®



- Monogenetic causes
- Syndrome related
- Timing differences
- Metabolic effects
- Body distribution
- Diet-responsive
- Drug-responsive
- Environmental causes

Genetic Disorders of Obesity Program

Referral



Age >1 yo
BMI > 97% prior to age 5

Evaluation



Endocrinologist



Geneticist

Outcomes



Genetic Testing



**Pharmacologic
Therapy**

GDOP Patients May 2019 - July 2022





Patient Characteristics (n=108)

Mean (Range) or
Percent (n)

Age

6.7y (0.6-16.6)

Characteristics and Preliminary Outcomes



Diagnostic:
BBS5, ALMS1

Intriguing:
SH2B1, KSR2,
SIM1, RAI1



Isolation in a sea of “experts”


Facing barriers
at every turn

Carrying all of the
burdens

Struggling to get their
child seen as an individual

"I'm not a real easily shaken person, I'm not an easily offended person at all. And when we left I cried because [the pediatrician] was just so- Like [the pediatrician] just didn't listen, and it was just very frustrating."

So What Can You Do?



Study to Better Characterize Food-Related Behaviors in SMS



- Drs. Elsea and Sisley are conducting focus groups this weekend to better understand food-related behaviors in the SMS population
- Goal is to create a better questionnaire for clinical trial use
- Need caregivers of SMS individuals who are at least 6 years old
- Focus groups will be audio recorded for accurate transcription
- Saturday at 12:30p in Beeman A and additional virtual sessions

For more information, contact Stephanie Sisley 513-465-8701
or email Sisley.lab@bcm.edu